Cytonics Corporation has received US Patent No. US 12,195,521 B2 for its engineered A2M variant, CYT-108. This patent enhances its competitive position by expanding therapeutic applications and securing exclusivity for two decades. It strengthens barriers to entry, increases licensing opportunities, and supports funding initiatives for future product development.
